Literature DB >> 6946847

Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B.

K R Rai, J F Holland, O J Glidewell, V Weinberg, K Brunner, J P Obrecht, H D Preisler, I W Nawabi, D Prager, R W Carey, M R Cooper, F Haurani, J L Hutchison, R T Silver, G Falkson, P Wiernik, H C Hoagland, C D Bloomfield, G W James, A Gottlieb, S V Ramanan, J Blom, N I Nissen, A Bank, R R Ellison, F Kung, P Henry, O R McIntyre, S K Kaan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6946847

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  86 in total

1.  A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias.

Authors:  Hanna Jean Khoury; Guillermo Garcia-Manero; Gautam Borthakur; Tapan Kadia; Maria Cielo Foudray; Martha Arellano; Amelia Langston; Beverly Bethelmie-Bryan; Selena Rush; Kevin Litwiler; Sharon Karan; Heidi Simmons; Adam I Marcus; Mieke Ptaszynski; Hagop Kantarjian
Journal:  Cancer       Date:  2011-12-02       Impact factor: 6.860

Review 2.  The role of timed sequential chemotherapy in adult acute myelogenous leukemia.

Authors:  Xavier Thomas
Journal:  Curr Hematol Malig Rep       Date:  2008-04       Impact factor: 3.952

Review 3.  Bone marrow transplantation: a review.

Authors:  R E Hardy; E V Ikpeazu
Journal:  J Natl Med Assoc       Date:  1989-05       Impact factor: 1.798

Review 4.  What Is the Best Daunorubicin Dose and Schedule for Acute Myeloid Leukemia Induction?

Authors:  Priyanka Pophali; Mark Litzow
Journal:  Curr Treat Options Oncol       Date:  2017-01

5.  Prognostic value of the expression of phosphatase and tensin homolog and CD44 in elderly patients with refractory acute myeloid leukemia.

Authors:  Xiao Huang; Dongyun Li; Tiantian Li; B O Zhao; Xinyi Chen
Journal:  Oncol Lett       Date:  2015-05-06       Impact factor: 2.967

Review 6.  Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature.

Authors:  Kelly J Norsworthy; Amy E DeZern; Hua-Ling Tsai; Wesley A Hand; Ravi Varadhan; Steven D Gore; Ivana Gojo; Keith Pratz; Hetty E Carraway; Margaret Showel; Michael A McDevitt; Douglas Gladstone; Gabriel Ghiaur; Gabrielle Prince; Amy H Seung; Dina Benani; Mark J Levis; Judith E Karp; B Douglas Smith
Journal:  Leuk Res       Date:  2017-08-30       Impact factor: 3.156

Review 7.  Concise review: Leukemia stem cells in personalized medicine.

Authors:  Monica L Guzman; John N Allan
Journal:  Stem Cells       Date:  2014-04       Impact factor: 6.277

8.  Anthracycline dose intensification in acute myeloid leukemia.

Authors:  Hugo F Fernandez; Zhuoxin Sun; Xiaopan Yao; Mark R Litzow; Selina M Luger; Elisabeth M Paietta; Janis Racevskis; Gordon W Dewald; Rhett P Ketterling; John M Bennett; Jacob M Rowe; Hillard M Lazarus; Martin S Tallman
Journal:  N Engl J Med       Date:  2009-09-24       Impact factor: 91.245

Review 9.  Acute myeloid leukaemia: optimising treatment in elderly patients.

Authors:  Graham H Jackson; Penelope R A Taylor
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

10.  A polymorphism in the 3'-untranslated region of the NPM1 gene causes illegitimate regulation by microRNA-337-5p and correlates with adverse outcome in acute myeloid leukemia.

Authors:  Chi Keung Cheng; Tsz Ki Kwan; Chi Ying Cheung; Kitty Ng; Pei Liang; Suk Hang Cheng; Natalie P H Chan; Rosalina K L Ip; Raymond S M Wong; Vincent Lee; Chi Kong Li; Sze Fai Yip; Margaret H L Ng
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.